Leading-edge technologies in the fight against cancer
We are a next generation radiopharmaceutical company, taking cancer head on.
Thank you! Your submission has been received!
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
Enables the efficient expansion of surface targets for radioisotope delivery
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023. Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patient dosed expected in Q1 2024. Company released its first terbium-161 preclinical data, and announced additional isotope supply partnerships for actinium-225 and lead-212.